Proficio Capital Partners LLC Makes New Investment in Repligen Co. (NASDAQ:RGEN)

Proficio Capital Partners LLC acquired a new stake in shares of Repligen Co. (NASDAQ:RGEN) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 21,303 shares of the biotechnology company’s stock, valued at approximately $3,066,000.

A number of other institutional investors also recently modified their holdings of RGEN. Charles Schwab Investment Management Inc. raised its holdings in shares of Repligen by 4.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 377,900 shares of the biotechnology company’s stock worth $54,395,000 after acquiring an additional 14,521 shares during the last quarter. NBW Capital LLC boosted its stake in Repligen by 19.7% during the 4th quarter. NBW Capital LLC now owns 25,194 shares of the biotechnology company’s stock valued at $3,626,000 after purchasing an additional 4,152 shares during the last quarter. Norden Group LLC increased its holdings in Repligen by 10.2% during the 4th quarter. Norden Group LLC now owns 3,698 shares of the biotechnology company’s stock worth $532,000 after purchasing an additional 341 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Repligen by 89.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,057 shares of the biotechnology company’s stock worth $152,000 after purchasing an additional 499 shares during the last quarter. Finally, Nichols & Pratt Advisers LLP MA lifted its position in shares of Repligen by 11.1% during the fourth quarter. Nichols & Pratt Advisers LLP MA now owns 1,505 shares of the biotechnology company’s stock valued at $217,000 after purchasing an additional 150 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Price Performance

NASDAQ RGEN opened at $144.34 on Wednesday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company has a market cap of $8.09 billion, a PE ratio of -283.02, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $200.23. The firm’s 50-day simple moving average is $156.98 and its two-hundred day simple moving average is $148.49.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. Research analysts predict that Repligen Co. will post 1.72 earnings per share for the current year.

Insider Transactions at Repligen

In other news, Director Margaret Pax acquired 250 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the transaction, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.20% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on RGEN. TD Cowen assumed coverage on shares of Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $180.00 price target on shares of Repligen in a research report on Friday, February 21st. Canaccord Genuity Group boosted their price objective on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. Royal Bank of Canada raised their target price on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research report on Friday, February 21st. Finally, Evercore ISI assumed coverage on shares of Repligen in a report on Tuesday. They issued an “in-line” rating and a $155.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $178.64.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.